Teladoc Health (NYSE:TDOC) Posts Quarterly Earnings Results

Teladoc Health (NYSE:TDOC) announced its quarterly earnings results on Wednesday. The health services provider reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05, FiscalAI reports. The firm had revenue of $642.27 million for the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%. Teladoc Health updated its Q1 2026 guidance to -0.450–0.350 EPS and its FY 2026 guidance to -1.100–0.700 EPS.

Teladoc Health Stock Performance

Teladoc Health stock traded up $0.12 during trading hours on Wednesday, hitting $4.66. 6,231,922 shares of the stock traded hands, compared to its average volume of 6,577,333. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $11.55. The stock has a market capitalization of $826.12 million, a price-to-earnings ratio of -3.64 and a beta of 2.12. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.70 and a quick ratio of 2.60. The firm’s 50 day moving average price is $6.11 and its 200-day moving average price is $7.24.

Wall Street Analysts Forecast Growth

TDOC has been the topic of a number of recent research reports. Citigroup dropped their price objective on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Friday, January 9th. BMO Capital Markets assumed coverage on Teladoc Health in a research report on Thursday, November 13th. They issued a “market perform” rating and a $8.00 price target for the company. Zacks Research downgraded Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Barclays initiated coverage on shares of Teladoc Health in a report on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 target price for the company. Finally, Bank of America lowered their price target on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Tuesday, November 25th. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $9.12.

Insider Transactions at Teladoc Health

In related news, insider Adam C. Vandervoort sold 5,720 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total transaction of $42,842.80. Following the completion of the transaction, the insider owned 80,732 shares of the company’s stock, valued at $604,682.68. This trade represents a 6.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Carlos Nueno sold 3,897 shares of the company’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total transaction of $29,188.53. Following the completion of the sale, the insider directly owned 27,175 shares in the company, valued at approximately $203,540.75. The trade was a 12.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 33,288 shares of company stock worth $251,684 in the last ninety days. Corporate insiders own 0.58% of the company’s stock.

Institutional Trading of Teladoc Health

Several institutional investors have recently bought and sold shares of TDOC. Dimensional Fund Advisors LP raised its stake in shares of Teladoc Health by 8.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 7,494,255 shares of the health services provider’s stock worth $52,459,000 after buying an additional 605,061 shares during the period. Geode Capital Management LLC lifted its holdings in Teladoc Health by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 4,188,313 shares of the health services provider’s stock valued at $29,324,000 after purchasing an additional 18,394 shares in the last quarter. Nuveen LLC grew its position in shares of Teladoc Health by 38.7% in the fourth quarter. Nuveen LLC now owns 2,659,662 shares of the health services provider’s stock valued at $18,618,000 after purchasing an additional 742,240 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Teladoc Health by 11.1% during the third quarter. Ameriprise Financial Inc. now owns 2,284,697 shares of the health services provider’s stock worth $17,661,000 after purchasing an additional 227,385 shares in the last quarter. Finally, Man Group plc raised its position in shares of Teladoc Health by 113.8% during the 4th quarter. Man Group plc now owns 1,620,633 shares of the health services provider’s stock worth $11,344,000 after purchasing an additional 862,454 shares during the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.